Adagene, Inc.(NASDAQ : ADAG)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|MRK||Merck & Co., Inc.||-0.01%||78.32||0.7%||$1640.63m|
|JNJ||Johnson & Johnson||0.72%||161.26||0.7%||$1027.09m|
|BMY||Bristol-Myers Squibb Co.||1.11%||58.34||1.0%||$691.66m|
|LLY||Eli Lilly & Co.||0.55%||237.98||1.1%||$629.67m|
|AVIR||Atea Pharmaceuticals, Inc.||-2.89%||39.28||0.3%||$121.41m|
|CRVS||Corvus Pharmaceuticals, Inc.||-3.51%||4.95||0.7%||$109.87m|
|NVO||Novo Nordisk A/S||1.89%||102.34||0.1%||$90.55m|
|RPRX||Royalty Pharma Plc||3.59%||38.39||0.1%||$87.06m|
Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.